NAME: Federico GAGO
DATE OF BIRTH: 21st October, 1957
NATIONALITY: Spanish

ADDRESS: Department of Biomedical Sciences, University of Alcalá, Alcalá de Henares, E-28871 Madrid, Spain
Phone: +34-918 854 514
FAX: +34-918 854 591 (Department); +34-918 854 544 (Faculty)

DEGREES: Master's Degree in Pharmacy "Licenciado en Farmacia" (June 1979), Universidad Complutense; "Grado de Licenciado" (September 1979), Univ. Complutense (Madrid). Ph. D. "Doctor en Farmacia *cum laude*" (April 1987), Universidad de Alcalá (Madrid).

POSTDOC TRAINING: April 1987- September 1989, Physical Chemistry Laboratory, Oxford University, U.K. *Supervisor:* Dr. W. Graham Richards.

PREVIOUS APPOINTMENTS: Lecturer of Pharmacology (1980-87)
Assistant Professor (1989-2009)
Associate Director of NFCR Center for Computational Drug Design (Oxford, 2001-06)
Member of the Editorial Advisory Board of *Journal of Medicinal Chemistry* (2006-10)

CURRENT POSITION: Full Professor of Pharmacology at University of Alcalá (since November 2009)
Member of the Editorial Advisory Board of *Anti-Cancer Agents in Medicinal Chemistry* (formerly *Current Medicinal Chemistry - Anti-Cancer Agents*), since 2001.
Editor-in-Chief of *Journal of Computer-Aided Molecular Design,* since 2001.

MEMBERSHIPS: Spanish Biophysics Society (since 1992).
Spanish Society of Medicinal Chemistry (since 1993).
Spanish Association of Cancer Researchers (since 1994).
Spanish Society of Biochemistry and Molecular Biology (since 1997).
Spanish Pharmacological Society (since 2001).
American Chemical Society (since 2006).

A. SELECTED INTERNATIONAL PUBLICATIONS

A.1. BOOK CHAPTERS

Mendoza, J.; Gago, F. (1994) Molecular recognition of dinucleotides and amino acids by artificial receptors containing a bicyclic guanidinium subunit (pp. 79-99), in *Computational Approaches in Supramolecular Chemistry*, NATO ASI Series, Kluwer Academic Publishers · ISBN 0-7923-2767-5.

Gallego, J., de Pascual, B., Ortiz, A. R., Pisabarro, M. T., Gago, F. (1995) Molecular Electrostatic Potentials of DNA Base Pairs and Drug Chromophores in Relation to DNA Conformation and Bis-Intercalation by Quinoxaline Antibiotics and Ditercalinium (pp. 274-281), in *QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications* ed. J. R. Prous, S.A. · ISBN: 84-8124-079-6.

Ortiz, A. R., Pisabarro, M. T., Gago, F., Wade, R. C. (1995) Prediction of Drug Binding Affinities by Comparative Binding Energy Analysis: Application to Human Synovial Fluid Phospholipase A_2 Inhibitors (pp. 439-443), in *QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications* ed. J. R. Prous, S.A. · ISBN: 84-8124-079-6.

Wade, R. C., Ortiz, A. R., Gago, F. (1998) Comparative Binding Energy Analysis (pp. 19-34), in *3D-QSAR in Drug Design, Vol. 2: Ligand–Protein Interactions and Molecular Similarity*; Kubinyi, H., Folkers, G., Martin, Y. Eds. Kluwer-ESCOM, Drodrecht · ISBN: ISBN 0-7923-4792-7.

Gago, F. & Hurley, L. H. (2002) Devising a Structural Basis for the Potent Cytotoxic Effects of Ecteinascidin 743 (pp. 643-675), in *Small Molecule DNA and RNA Binders: From Synthesis to Nucleic Acid Complexes,* Demeunynck, C. Bailly & D. Wilson, Eds., Wiley-VCH (Weinheim, Alemania) · ISBN 3-527-30595-5.

Damborsky J., Kmunicek J., Jedlicka T., Luengo S., Gago F., Ortiz A.R., Wade R.C. Rational Re-design of Haloalkane Dehalogenases Guided by Comparative Binding Energy Analysis (pp. 79-96), in *Enzyme Functionality: Design, Engineering and Screening*. Svendsen, A. (Ed.) Marcel Decker (New York) · ISBN 0-

8247-4709-7.

Gago, F. (2005) Pharmacological Properties of Nimesulide: Structural Aspects of Cyclooxygenase (COX) Activity and COX-2 Inhibition by Nimesulide (pp.162-173), in *Nimesulide: Actions and Uses*. K. Rainsford (editor) Birkhäuser Verlag AG (Basel/Switzerland) · ISBN 3-7643-7068-8.

Gago, F. (2006) Computer simulations of drug-DNA interactions: A personal journey (pp. 152-189), in *Sequence-Specific DNA Binding Agents*, Michael Waring (editor), Royal Society of Chemistry (United Kingdom) · ISBN 0-85404-370-5.

Gago, F. & Moreno, S. (2009) Trabectedin, in *Encyclopedia of Cancer*. Manfred Schwab (Editor-in-Chief), Springer (Germany) · ISBN 978-3-540-36847-2.

Morreale, A. & Gago, F. (2012) COMparative BINding Energy (COMBINE) analysis as a structure-based 3D-QSAR method (pp. 244-272), in *Physico-Chemical and Computational Approaches to Drug Discovery*, *F. Javier Luque & Xavier Barril (editors),* Royal Society of Chemistry (Great Britain) · ISBN-10: 1849733538.

A.2. PAPERS IN REFEREED JOURNALS (last 6 years)

108. Familiar, O.; Munier-Lehmann, H.; Negri, A.; Gago, F.; Douguet, D.; Rigouts, L.; Hernández, A.I.; Camarasa, M.J.; Pérez-Pérez, M.J. "Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase". ChemMedChem, 3(7): 1083–1093 (2008).

109. Pérez-Pérez, M.J.; Priego, E.-M.; Hernández, A.I.; Familiar, O.; Camarasa, M.J.; Negri, A.; Gago, F.; Balzarini, J. "Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future". Medicinal Research Reviews, 28(5):797–820 (2008).

110. Casado, J.A.; Río, P.; Marco, E.; García-Hernández, V.; Domingo, A.; Pérez, L.; Tercero, J.C.; Vaquero, J.J.; Albella, B.; Gago, F.; Bueren, J.A. "The relevance of the Fanconi anemia pathway in the response of human cells to trabectedin". Molecular Cancer Therapeutics, 7(5): 1309–1318 (2008).

111. Matesanz, R.; Barasoain, I.; Yang, C.-G.; Wang, L.; Li, X.; de Inés, C.; Coderch, C.; Gago, F.; Jiménez-Barbero, J.; Andreu, J.M.; Fang, W.-S.; Díaz, J.F. "Optimization of taxane binding to microtubules. Binding affinity dissection and incremental construction of a high-affinity analogue of paclitaxel". Chemistry & Biology, 15(6): 573–585 (2008).

112. Pande, V. ; Ramos, M.J. ; Gago, F. "The protein kinase inhibitor balanol: structure–activity relationships and structure-based computational studies". Anti-Cancer Agents - Medicinal Chemistry, 8(6): 638–645 (2008).

113. Rico, E.; Alzate, J.F.; Arias, A.A.; Gago, F.; Moreno, D.; Clos, J.; Moreno, I.; Domínguez, M.; Jiménez-Ruiz, A. "*Leishmania infantum* expresses a mitochondrial nuclease homologous to EndoG that migrates to the nucleus in response to an apoptotic stimulus". Molecular & Biochemical Parasitology, 163(1): 28-38 (2009).

114. Balzarini, J.; van Daele, I.; Negri, A.; Solaroli, N.; Karlsson, A.; Liekens, S.; Gago, F.; van Calenbergh, S. "Human mitochondrial thymidine kinase (TK-2) is selectively inhibited by 3'-thiourea derivatives of β-thymidine. Identification of residues crucial for both inhibition and catalytic activity". Molecular Pharmacology, 75(5):1127–1136 (2009).

115. Bronckaers, A.; Aguado, L.; Negri, A.; Camarasa, M.J.; Balzarini, J.; Pérez-Pérez, M.J.; Gago, F.; Liekens,S. "Identification of Asp203 in human thymidine phosphorylase as an important residue for both catalysis and non-competitive inhibition by the small molecule "crystallization chaperone" 5'-O-tritylinosine (KIN59)". Biochemical Pharmacology, 78(3):231-240 (2009).

116. Leal, J-F. M.; García-Hernández, V.; Moneo, V.; Domingo, D.; Bueren-Calabuig, J.A.; Negri, A.; Gago, F.; Guillén-Navarro, M.J.; Avilés, P.; Cuevas, C.; García-Fernández, L.F.; Galmarini, C.M. "Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines". Biochemical Pharmacology, 78(2):162-170 (2009).

117. Bronckaers, A.; Gago, F.; Balzarini, J.; Liekens, S. "The dual role of thymidine phosphorylase in cancer development and cancer chemotherapy". Medicinal Research Reviews, 29(6):903-953 (2009).

118. Negri, A.; Rodríguez-Larrea, D.; Marco, E.; Jiménez-Ruiz, A.; Sánchez-Ruiz, J.M.; Gago, F. "Protein-protein interactions at an enzyme-substrate interface: characterization of transient reaction intermediates throughout a full catalytic cycle of *Escherichia coli* thioredoxin reductase". Proteins: Structure, Function & Bioinformatics, 78(1):36-51 (2010).

119. Gil-Redondo, R.; Klett, J.; Gago, F.; Morreale, A. "gCOMBINE: a graphical user interface to perform structure-based Comparative Binding Energy (COMBINE) analysis on a set of ligand-receptor complexes". Proteins: Structure, Function & Bioinformatics, 78(1):162–172 (2010).

120. Casanova, E.; Priego, E.M.; Jimeno, M. L.; Aguado, L.; Negri, A.; Gago, F.; Camarasa, M.J.; Pérez-Pérez, MJ. "Intramolecular cation- π interactions as the driving force to restrict the conformation of certain nucleosides". Journal of Organic Chemistry, 75(6):1974-81 (2010)

121. Van Poecke, S.; Negri, A.; Gago, F.; Van Daele, I.; Solaroli, N.; Karlsson, A.; Balzarini, J.; Van Calenbergh, S. "3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine Analogues as Potent and Selective Inhibitors of Human Mitochondrial Thymidine Kinase." Journal of Medicinal Chemistry, 53(7):2902-12 (2010).

122. Peón, A. ; Otero, J.M. ; Tizón, L.; Prazeres, V.F.V.; Llamas-Saiz, A.L.; Fox, G.C.; van Raaij, M.J.; Lamb, H.; Hawkins, A.R. ; Gago, F. ; Castedo, L. ; González-Bello, C. "Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids". ChemMedChem, 5(10):1726–1733 (2010).

123. Leal, J.F.M.; Martínez-Díez, M.; García-Hernández, V.; Moneo, V.; Domingo, A.; Bueren-Calabuig, J.A.; Negri, A.; Gago, F.; Guillén-Navarro, M.J.; Avilés, P.; Cuevas, C.; García-Fernández, L.F.; Galmarini, C.M. "PM01183, a new DNA minor-groove covalent binder with potent in vitro and in vivo antitumor activity." British Journal of Pharmacology 161(5):1099–1110 (2010).

124. Van Poecke, S.; Negri, A.; Janssens, J.; Solaroli, N.; Karlsson, A.; Gago, F.; Balzarini, J.; Van Calenbergh, S. "Synthesis, modeling and evaluation of 3'-(1-aryl-1H-tetrazol-5-ylamino)-substituted thymidine analogues as potent and selective human mitochondrial thymidine kinase inhibitors." Organic & Biomolecular Chemistry 9(3):892–901 (2011).

125. Camacho-Artacho, M.; Abet, V.; Frutos, L. M.; Gago, F.; Alvarez-Builla G., J.; Burgos, C. "Unusual approach to 3-aryl-2-aminopyridines through a radical mechanism: synthesis and theoretical rationale from quantum mechanical calculations". Journal of Organic Chemistry 76(5):1452–1455 (2011).

126. Díez-Dacal, B.; Gayarre, J.; Gharbi, S.; Timms, J.F.; Coderch, C.; Gago, F.; Pérez-Sala, D. "Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A1: implications for anti-tumoral activity". Cancer Research, 71(12): 4161–4171 (2011).

127. Bueren-Calabuig, J.A.; Giraudon, C.; Galmarini, C.M.; Egly, J.M.; Gago, F. "Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations". Nucleic Acids Research, 39(18):8248–8257 (2011).

128. Feuerhahn,S.; Giraudon,C.; Martínez-Díez,M.; Bueren-Calabuig,J.A.; Galmarini,C.M.; Gago,F.; Egly, J.M. "XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic tetrahydroisoquinoline alkaloids". Chemistry & Biology, 18(8):988–999 (2011).

129. Cortés Cabrera, A.; Gil-Redondo, R.; Perona, A.; Gago, F.; Morreale, A. "VSDMIP 1.5: an automated structure- and ligand-based virtual screening platform with a PyMOL graphical user interface". Journal of Computer-Aided Molecular Design, 25(9):813–824 (2011).

130. Bueren-Calabuig, J.A.; Coderch, C.; Rico, E.; Jiménez-Ruiz, A.; Gago, F. "Mechanistic insight into the catalytic activity of ββα-metallonucleases from computer simulations: *Vibrio vulnificus* periplasmic nuclease as a test case". ChemBioChem, 12(17): 2615-2622 (2011).

131. Coderch C, Morreale A, Gago F. "Tubulin-based structure-affinity relationships for antimitotic *Vinca* alkaloids". Anticancer Agents Medicinal Chemistry. 12(3):219-25 (2012).

132. Bueren-Calabuig, J.A.; Negri, A.; Morreale, A.; Gago, F. "Rationale for the opposite stereochemistry of the major monoadducts and interstrand crosslinks formed by mitomycin C and its decarbamoylated analogue at CpG steps in DNA and the effect of cytosine modification on reactivity". Organic & Biomolecular Chemistry,

10(8): 1543–1552 (2012).

133. Cortés-Cabrera, A.; Gago, F.; Morreale, A. "A reverse combination of structure-based and ligand-based strategies for virtual screening". Journal of Computer-Aided Molecular Design, 26(3):319-27 (2012).

134. Coderch, C.; Klett, J.; Morreale, A.; Díaz, J.F.; Gago, F. “Comparative Binding Energy (COMBINE) analysis supports a proposal for the binding mode of epothilones to β-tubulin”. ChemMedChem. 7(5):836-843 (2012).

135. Van de Voorde, J.; Gago, F.; Vrancken, K.; Liekens, S.; Balzarini, J. “Characterization of pyrimidine nucleoside phosphorylase of *Mycoplasma hyorhinis*: implications for the clinical efficacy of nucleoside analogues”. Biochemical Journal, 445(1):113-123 (2012).

136. Priego, E.-M.; Karlsson, A.; Gago, F.; Camarasa, M.-J.; Balzarini, J.; Pérez-Pérez, M.-J. “Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications”. Current Pharmaceutical Design, 18(20):2981-2994 (2012).

137. Balzarini, J.; Gago, F.; Kulik, W.; van Kuilenburg, A.B.P.; Karlsson, A.; Peterson, M.A.; Robins, M.J. “Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase to inhibition of orotidylate decarboxylase, an early event in the *de novo* pyrimidine nucleotide biosynthesis pathway”. Journal of Biological Chemistry, 287(36):30444-30454 (2012).

138. Cortés Cabrera, A.; Klett, J.; Gomes Dos Santos, H.; Perona, A.; Gil-Redondo, R.; Francis, S.M.; Priego, E.M.; Gago, F.; Morreale, A. “CRDOCK: an ultrafast multipurpose protein-ligand docking tool”. Journal of Chemical Information and Modeling, 52(8):2300-2309 (2012).

139. Cortés Cabrera, A.; Gago, F.; Morreale, A.; Abad-Zapatero, C. “AtlasCBS: A web server to map and explore chemico-biological space”. Journal of Computer-Aided Molecular Design, 26(9):995-1003 (2012).

140. Klett, J.; Núñez-Salgado, A.; Dos Santos, H.G.; Cortés-Cabrera, A.; Perona, A.; Gil-Redondo, R.; Abia, D.; Gago, F.; Morreale, A. “MM-ISMSA: an ultra-fast and accurate scoring function for protein-protein docking”. Journal of Chemical Theory and Computation, 8, 3395−3408 (2012).

141. Gago, F. “Molecular simulations of drug-receptor complexes in anticancer research”. Future Medicinal Chemistry, 4(15) 1961-1970 (2012).

142. Peón, A.; Coderch, C.; Gago, F.; González-Bello, C. “Comparative Binding Energy (COMBINE) Analysis for Understanding the Binding Determinants of Type II Dehydroquinase Inhibitors”. ChemMedChem, 8(5) 740–747 (2013).

143. Coderch, C.; Tang, Y.; Klett, J.; Zhang, S.-E.; Ma, Y.-T.; Shaorong, W.; Matesanz, R.; Pera, B.; Canales, A.; Jiménez-Barbero, J.; Morreale, A.; Díaz, J.F.; Fang, W.-S.; Gago, F. “A structure-based design of new C2- and C13-substituted taxanes: tubulin binding affinities and quantitative structure-activity relationships using Comparative Binding Energy (COMBINE) analysis”. Organic & Biomolecular Chemistry, 11 (18) 3046 - 3056 (2013).

144. Casanova, E.; Moreno, D.; Gigante, A.; Rico, E.; Oliva, C.; Camarasa, M.-J.; Gago, F.; Jiménez-Ruiz, A.; Pérez-Pérez, M.-J. "5'-trityl-substituted thymidine derivatives as a novel class of antileishmanial agents: *Leishmania infantum* EndoG as a potential target". ChemMedChem, 8(7):1161-1174 (2013).

145. Toro, M. A.; Sánchez-Murcia, P.A.; Moreno, D.; Ruiz Santa Quiteria, M.; Alzate, J.F.; Negri, A.; Camarasa, M.J.; Gago, F.; Velázquez, S.; Jiménez-Ruiz, A. “Probing the dimerization interface of *Leishmania infantum* trypanothione reductase with site-directed mutagenesis and short peptides”. ChemBioChem, 14(10):1212-1217 (2013).

146. Gherbovet, O.; Coderch, C.; Garcia Alvarez, M. C.; Bignon, J.; Thoret, S.; Martin, M.-T.; Guéritte, F.; Gago, F.; Roussi, F. “Synthesis and Biological Evaluation of a New Series of Highly Functionalized 7’-Homo-Anhydrovinblastine Derivatives”. Journal of Medicinal Chemistry, 56(15):6088–6100 (2013).

147. Cortés-Cabrera, A.; Morris, G.M.; Finn, P.W.; Morreale, A.; Gago, F. “Comparison of Ligand and Target Descriptors for Side-effect Prediction and Network Analysis in Polypharmacology”. British Journal of Pharmacology, 170(3):557–567 (2013).

148. Martínez, S.; Pérez, L.; Galmarini, C.; Aracil, M.; Tercero, J.C.; Gago, F.; Albella, B.; Bueren, J.A. "Inhibitory effects of marine-derived DNA-binding antitumour tetrahydroisoquinolines on the Fanconi anemia pathway". British Journal of Pharmacology, 170(4):871–882 (2013).

149. Parayil, A.; Gago, F. "New horizons in pharmaceutical biotechnology by melding biology and engineering". Current Opinion in Biotechnology, 24(6):1069–1071 (2013).

150. Klett, J.; Cortés-Cabrera, A.; Gil-Redondo, R.; Gago, F.; Morreale, A. "ALFA: Automatic Ligand Flexibility Assignment". Journal of Chemical Information and Modeling, in press (2014)

151. Coderch, C.; Lence, E.; Peón, A.; Lamb, H.; Hawkins, A.R.; Gago, F.; González-Bello, C. "Mechanistic insight into the reaction catalysed by bacterial type II dehydroquinases". Biochemical Journal, in press (2014).

Resumé

Federico Gago studied Pharmacy at Complutense University, Madrid, and followed post-doctoral studies at the Physical Chemistry Laboratory, Oxford University, under the supervision of Prof. W. Graham Richards. He teaches Pharmacology at the Schools of Pharmacy and Medicine in the University of Alcalá (Madrid), one of the oldest European universities, where he is a Full Professor in the Department of Biomedical Sciences. He was Associate Director of the NFCR Center for Computational Drug Design (Oxford) from 2001 to 2006 and a member of the Editorial Advisory Board of *Journal of Medicinal Chemistry* from 2006 to 2010. Since 2001 he has been serving as an Editor-in-Chief for *Journal of Computer-Aided Molecular Design* and as a member of the Editorial Advisory Board for *Anti-Cancer Agents in Medicinal Chemistry* (formerly *Current Medicinal Chemistry - Anti-Cancer Agents*).

Prof. Gago has authored more than 150 research papers in specialized scientific journals and has published several reviews and book chapters. His research interests are in the areas of structure-based drug design, receptor-based structure-activity relationships, and computer simulations of drug-targeted biomolecular systems including DNA, enzymes and pharmacological receptors.